AbbVie (ABBV) Receives News Sentiment Score of 0.17
Headlines about AbbVie (NYSE:ABBV) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AbbVie earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.1062567928746 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern’s scoring:
- New report examines the Global general anesthesia drugs market trends & industry forecast by 2017 – 2025 (whatech.com)
- AndroGel Maker Hit with $150 Million in Punitive Damages at Trial (injurylawyer-news.com)
- AbbVie pill combo Mavyret gets FDA OK for all forms of hepatitis C (chicago.suntimes.com)
- Artemis Investment Management LLP Adjusts Its Stake in AbbVie Inc. (ABBV) – Modern Readers (modernreaders.com)
- Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data (finance.yahoo.com)
A number of research firms have recently issued reports on ABBV. Piper Jaffray Companies restated a “buy” rating and issued a $85.00 target price on shares of AbbVie in a report on Thursday, August 3rd. Cowen and Company set a $70.00 target price on AbbVie and gave the company a “hold” rating in a report on Sunday, July 30th. BidaskClub lowered AbbVie from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Vetr upgraded AbbVie from a “hold” rating to a “buy” rating and set a $76.28 target price for the company in a report on Wednesday, July 26th. Finally, Credit Suisse Group restated a “neutral” rating and issued a $74.00 target price (up previously from $65.00) on shares of AbbVie in a report on Thursday, July 20th. Nine equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $74.66.
AbbVie (NYSE ABBV) traded up 0.77% during trading on Wednesday, reaching $72.02. 4,536,324 shares of the company’s stock traded hands. The firm has a market cap of $114.62 billion, a PE ratio of 17.71 and a beta of 1.50. The firm has a 50 day moving average price of $72.12 and a 200-day moving average price of $66.41. AbbVie has a 12 month low of $55.06 and a 12 month high of $75.04. AbbVie also was the target of some unusual options trading activity on Monday. Investors bought 278 put options on the company. This represents an increase of approximately 121% compared to the average volume of 126 put options.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 154.76%. The business had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. During the same quarter in the prior year, the business earned $1.26 EPS. AbbVie’s quarterly revenue was up 7.6% on a year-over-year basis. On average, analysts forecast that AbbVie will post $5.52 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be given a dividend of $0.64 per share. The ex-dividend date is Wednesday, July 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 3.55%. AbbVie’s payout ratio is presently 62.90%.
In other AbbVie news, CFO William J. Chase sold 38,300 shares of the stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the transaction, the chief financial officer now owns 209,043 shares in the company, valued at approximately $13,660,960.05. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 71,235 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $65.49, for a total transaction of $4,665,180.15. Following the transaction, the chairman now owns 349,462 shares in the company, valued at approximately $22,886,266.38. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 600,026 shares of company stock worth $41,852,724. Company insiders own 0.23% of the company’s stock.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.